SCHEMBL7042402

SCHEMBL7042402

CC(C)(C)Oc1cncc(CC2CC3CCN2C3)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 9/20 0.43
CHRNA4 P43681 7/20 0.43
CHRNA7 P36544 1/20 0.43
GAA P10253 1/20 0.35
ALPG P10696 1/20 0.35
GFER P55789 1/20 0.35
DAPK3 O43293 1/20 0.34
ROCK2 O75116 1/20 0.34
PRKCG P05129 1/20 0.34
PIM1 P11309 1/20 0.34
RPS6KB1 P23443 1/20 0.34
AKT1 P31749 1/20 0.34
LIMK1 P53667 1/20 0.34
CDK5 Q00535 1/20 0.34
PRKCD Q05655 1/20 0.34
PAK1 Q13153 1/20 0.34
STK3 Q13188 1/20 0.34
ROCK1 Q13464 1/20 0.34
DYRK1A Q13627 1/20 0.34
CDC42BPA Q5VT25 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7045708 0.93 CHRNB2 (0.51) CHRNB2CHRNA4CHRNA7GAAALPG
SCHEMBL7046934 0.92 CHRNB2 (0.37) CHRNB2CHRNA4CHRNA7DAPK3ROCK2
SCHEMBL7040540 0.86 CHRNB2 (0.46) CHRNB2CHRNA4CHRNA7GAAALPG
SCHEMBL7042417 0.84 CHRNB2 (0.44) CHRNB2CHRNA4CHRNA7DAPK3ROCK2
SCHEMBL7046955 0.83 CHRNB2 (0.43) CHRNB2CHRNA4CHRNA7GAAALPG
SCHEMBL7045702 0.78 CHRNB2 (0.55) CHRNB2CHRNA4CHRNA7GAAALPG
SCHEMBL7045529 0.78 CHRNB2 (0.49) CHRNB2CHRNA4CHRNA7DAPK3ROCK2
SCHEMBL7047384 0.78 CHRNB2 (0.39) CHRNB2CHRNA4CHRNA7DAPK3ROCK2
SCHEMBL7042274 0.76 CHRNB2 (0.52) CHRNB2CHRNA4CHRNA7GAAALPG
SCHEMBL7042416 0.76 CHRNB2 (0.44) CHRNB2CHRNA4CHRNA7DAPK3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030045523-A1 Nicotinic cholinergic receptor antagonists SCHMITT JEFFREY DANIEL (US) 2003-03-06 US disclosed
US-6432975-B1 AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT TARGACEPT, INC. 2002-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045523-A1 Nicotinic cholinergic receptor antagonists CHRNG, CHRNB1, CHRNA1 CHRNB2 9/4885CHRNA4 13/4885CHRNA7 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.